aTyr Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $27.3M
- Price
- $0.2783
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.80%
- Volume
- 1.1M
About
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Quick stats
Shares outstanding98.1M
Computed float92.3M
Float / shares94.0%
Cash runway (months)11.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001339970
Websitehttps://www.atyrpharma.com
AI Summary
AI-generated1/11
majorbullishclinical trial
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in chronic pulmonary sarcoidosis with restrictive lung disease, with study activities expected to begin in Q4 2026.
The global, randomized, placebo-controlled 54-week trial will enroll up to approximately 372 patients, using FVC change at week 48 as the primary endpoint, focusing on the restrictive subgroup that showed clinically meaningful benefit in the prior Phase 3 EFZO-FIT study.
The company notes future development will require additional capital through equity or debt offerings, partnerships, or licensing — a funding overhang alongside the execution risk of the new trial.
Red flags
- Company explicitly states it will need to raise additional capital (equity or debt) to fund the Phase 3 study — dilution risk
- New Phase 3 follows a subgroup-based pivot after the EFZO-FIT study; regulatory pathway still unproven